Lipocine releases late breaking presentation on LPCN 1148 Phase 2 results

Lipocine announced that results of its Phase 2 study evaluating LPCN 1148 are being presented at The American Association for the Study of Liver Diseases, or AASLD, The Liver Meeting 2023, taking place in Boston MA. The results are featured in a late-breaking oral presentation and e-poster by Dr. Arun Sanyal, MD, Director, Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, Virginia Commonwealth University, advisor to Lipocine. The Phase 2 proof of concept study is a 52-week ongoing randomized placebo-controlled study in sarcopenic male patients with cirrhosis on the liver transplant waitlist. After week 24, all patients enter a single arm open-label extension, or OLE, stage of the study and receive LPCN 1148. The purposes of the OLE are to evaluate the safety and efficacy of continued exposure with LPCN 1148 in this population, and to increase the number of participants on LPCN 1148 treatment. “We are very pleased to share the data from our successful Phase 2 study of LPCN 1148 with the hepatology community at this year’s Liver Meeting. The data show that LPCN 1148 improved multiple additional clinically meaningful and surrogate outcomes, including hepatic encephalopathy. An Open Label Extension is now ongoing, and we look forward to reporting further data in Q1 2024,” said Dr. Mahesh Patel, President and CEO of Lipocine.